What question did this study set out to answer?

To evaluate the prevalence, molecular genetic features, and diagnostic implications of unusual CD34-negative or CD34-dim myeloblasts in presumptive myelodysplastic syndrome cases.

December 23, 2024Archives of Pathology & Laboratory MedicineOpen Access

The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

FSFnu Sameeta WWWei Wang FJFatima Zahra Jelloul

Discussion

Member takes

Overview

Retrospective study uncovers distinct genetic abnormalities in myelodysplastic syndromes with CD34-deficient myeloblasts, indicating reclassification risk to acute myeloid leukemia.

Key Points

To evaluate the prevalence, molecular genetic features, and diagnostic implications of unusual CD34-negative or CD34-dim myeloblasts in presumptive myelodysplastic syndrome cases.
Retrospectively reviewed over 2,000 flow cytometry immunophenotyping assays performed for suspected myelodysplastic syndrome across a 5-year period.
Excluded cases of overt acute myeloid leukemia (blasts ≥20%) and chronic myelomonocytic leukemia to analyze abnormal blast immunophenotypes and molecular genetic profiles.
Among approximately 800 confirmed myeloid neoplasm cases, 31 (4%) displayed CD34-negative or partially negative blasts, compared to 96% exhibiting typical primitive immunophenotypes.
Recurrent genetic abnormalities were present in 13 of 31 cases (42%), including NPM1 mutations (n=10), KMT2A rearrangement (n=1), and t(3;5)(q25.3;q35.1) (n=2); modern 2022 WHO and ICC guidelines reclassify 69% and 54% of these cases as acute myeloid leukemia, respectively.
Eight cases (26%) harbored multihit TP53 mutations, with 6 of those 8 ultimately diagnosed with or rapidly progressing to pure erythroid leukemia.

Cite This Study

Sameeta et al. (2024) studied this question.

synapsesocial.com/papers/6aaa2f8ebf5b892176fca8fa https://doi.org/10.5858/arpa.2024-0228-oa

View Full Paper

Ask AI

Bookmark

December 23, 2024Archives of Pathology & Laboratory MedicineOpen Access

The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

FSFnu Sameeta WWWei Wang FJFatima Zahra Jelloul

Discussion

Member takes

Overview

Retrospective study uncovers distinct genetic abnormalities in myelodysplastic syndromes with CD34-deficient myeloblasts, indicating reclassification risk to acute myeloid leukemia.

Key Points

To evaluate the prevalence, molecular genetic features, and diagnostic implications of unusual CD34-negative or CD34-dim myeloblasts in presumptive myelodysplastic syndrome cases.
Retrospectively reviewed over 2,000 flow cytometry immunophenotyping assays performed for suspected myelodysplastic syndrome across a 5-year period.
Excluded cases of overt acute myeloid leukemia (blasts ≥20%) and chronic myelomonocytic leukemia to analyze abnormal blast immunophenotypes and molecular genetic profiles.
Among approximately 800 confirmed myeloid neoplasm cases, 31 (4%) displayed CD34-negative or partially negative blasts, compared to 96% exhibiting typical primitive immunophenotypes.
Recurrent genetic abnormalities were present in 13 of 31 cases (42%), including NPM1 mutations (n=10), KMT2A rearrangement (n=1), and t(3;5)(q25.3;q35.1) (n=2); modern 2022 WHO and ICC guidelines reclassify 69% and 54% of these cases as acute myeloid leukemia, respectively.
Eight cases (26%) harbored multihit TP53 mutations, with 6 of those 8 ultimately diagnosed with or rapidly progressing to pure erythroid leukemia.

Cite This Study

Sameeta et al. (2024) studied this question.

synapsesocial.com/papers/6aaa2f8ebf5b892176fca8fa https://doi.org/10.5858/arpa.2024-0228-oa

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark